Autosomal Dominant Polycystic Kidney Disease Treatment Market

Autosomal Dominant Polycystic Kidney Disease Treatment Market Snapshot (2023 to 2033)

The global autosomal dominant polycystic kidney disease treatment market is anticipated to attain a valuation of US$ 1,197.3 million in 2023 and is projected to reach US$ 2,140 million by 2033, trailing at a CAGR of 5.97% during the forecast period.

The polycystic kidney disease market is propelled by surging incidences of renal failure or dialysis. This disease can be caused by a number of factors, including a family history of kidney problems, a rare genetic mutation, kidney failure, or people undergoing dialysis, which boosts the market growth.

Another crucial factor driving the growth of polycystic kidney disease market is the increasing healthcare expenditure which helps in enhancing its infrastructure. Moreover, growing initiatives by public and private organizations to spread awareness is expected to expand the polycystic kidney disease treatment market. High disposable income and surging demand for advanced treatment and innovative solutions will result in the growth of polycystic kidney disease treatment industry. Also, favourable government policies and growing awareness about genetic diseases among people will positively benefit the growth of this market.

2018 to 2022 Autosomal dominant polycystic kidney disease treatment Demand Analysis vs. Forecast 2023 to 2033

The industry for Autosomal dominant polycystic kidney disease treatment recorded a valuation of US$ 954 million in 2018, while growing at a CAGR of 4.65% during the historical period. The market's growth is driven by rising number of research and development activities. This will provide lucrative opportunities for growth of polycystic kidney disease treatment market. Also, increasing drug approvals and launches will further fuel the market’s growth rate.

On the other hand, increasing investments for the development of advanced technologies and growth in the number of emerging markets will further provide lucrative opportunities for the polycystic kidney disease market growth during the projected period.Likewise, Leading ADPKD companies like, Galapagos NV, Anakuria Therapeutics, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, Chinook Therapeutics, and few others are developing novel Autosomal dominant polycystic kidney disease drugs that can be available in the market in the forthcoming years which will benefit the industry’s growth.

‘JYNARQUE’ is a novel drug in the form of pill which is taken twice a day that delays the growth of cysts and has been shown to regulate kidney function. It is a long-term use drug, thus extending the timeframe before a person requires dialysis or a kidney transplant, though it doesn’t cure polycystic kidney disease. This drug was developed by Otsuka Pharmaceuticals. Thus, arrival of similar kind of drugs will present growth opportunities for the market’s growth. After a comprehensive analysis of above-mentioned factors and developments, the revenue growth of Autosomal dominant polycystic kidney disease treatment market is projected to be worth US$ 2,140 million by end of the forecast period, while exhibiting a CAGR of 5.97%.

Which are Some Prominent Drivers spearheading the Autosomal dominant polycystic kidney disease treatment market?

Strong drug pipeline bolstering the industry growth

The adoption of promising Autosomal Dominant Polycystic Kidney Disease Treatment therapies in the pipeline like GLPG2737, Bardoxolone methyl, Tesevatinib, Venglustat, AT 20494, RGLS 8429, AL 01211, XRx-008, PXL770, and few others is expected to propel the growth of this market. Furthermore, the market size is anticipated to grow owing to expected launch of potential therapies and a rise in the diagnosed prevalent population of polycystic kidney disease around the world. Likewise, tolvaptan (Jynarque/Jinarc/Samsca) is the only approved drug developed by Otsuka Pharmaceuticals' in the world for the treatment of adults suffering from autosomal dominant polycystic kidney disease. This is anticipated to support market growth during the forecast period.

On the other hand, technological advancements in diagnostic procedures, as a result of a greater stress on early stage diagnosis, have condensed undiagnosed cases. Therefore, continuously increasing cases of diagnosed autosomal dominant polycystic kidney disease is providing opportunities for companies to launch new therapies in the concerned market. Also, advances are being made in determining the genetic causes of polycystic kidney disease, non-invasive monitoring, and in foreseeing disease progression, all of which will aid in management of disease and will help the market grow. In addition, pre-symptomatic diagnosis and its application in the care and management of Autosomal dominant polycystic kidney disease patients also contribute to the expansion of this market during the forecast period.

The polycystic kidney disease drug pipeline is strong and dynamic, with many products being created across different stages for autosomal dominant polycystic kidney disease, thereby driving the growth of autosomal dominant polycystic kidney disease treatment market. Furthermore, the discovery of biomarkers for early detection of polycystic patients at high risk of progression will aid in better managing polycystic disease patients and preventing disease progression.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the challenges expected to be Faced by the Market?

Discontinuation of treatment to restrain market expansion

The discontinuation of treatment due to inability to tolerate aquaretic agents, hepatic adversative events (abnormal liver function tests), progression of disease, and chronic kidney injury.

Also, dearth of awareness and limited knowledge of polycystic kidney disease among the patients and primary care physicians are noteworthy shortcomings in this market, that are most likely to hamper market’s growth.

Region-Wise Insights

What are the growth prospects in North America?

North America to dominate the market with maximum share

North America is expected to dominate the polycystic kidney disease market by accumulating market share of 39.5% by end of the forecast period. The growth is attributed to technological advancements and increasing number of government initiatives taken by pharmaceutical organizations to generate novel formulation in this region.

Rising inclination of patients towards early-stage diagnosis and treatment, favorable reimbursement policies and strong geographical presence of the leading players in the region is also anticipated to fuel growth of the polycystic kidney disease treatment market during the projected period. On the other hand, advancements in diagnosis and tests, increasing per capita income, and easy availability of drugs are expected to propel the polycystic kidney disease therapeutics market in the region.

What is the growth outlook in East Asia?

East Asia driving growth with fastest CAGR

The market in East Asia is anticipated to grow with fastest CAGR of 6.2% during the forecast period. This region is expected to be third largest market for polycystic kidney disease treatment by 2033. The regional growth is attributable to due to surging number of government initiatives for spreading awareness and presence of generic manufacturers. Also, growing awareness and increasing number of patient suffering from kidney diseases is leading to market expansion in this region.

Also, accessibility of technologically advanced products, and the presence of newly-incepted state-of-the-art healthcare facilities is leading to expansion of regional market. Increasing geriatric population, lifestyle stress, a huge population base, improved quality of diagnosis, and surging patient affordability are also aiding in market expansion.

Recently, China has proven to be an promising market for medical devices. In March 2019, the Chinese government decreased the Value Added Tax for medical manufacturing companies from 13.30% to 13.%. This is most likely to benefit domestic manufacturers of medical equipment’s, which will lead to growth of autosomal dominant polycystic kidney disease treatment market in East Asia.

Category wise Insights

By treatment type, which segment will possess market hegemony?

Pain and Inflammation segment to witness highest demand

This segment is expected to accumulate highest market share of 37.4% by end of the forecast period. Pain and inflammation treatment type segment is anticipated to experience highest demand since it is the first line therapy for the treatment of autosomal dominant polycystic kidney disease. For severe pain, non-opioid analgesics and conventional interventions are used first, before considering opioid analgesics. If pain still continues use of surgical interventions like renal cyst decortication, renal denervation and nephrectomy that can target pain induced by renal or hepatic cysts is advised by healthcare professionals which is expected to support segment’s growth.

There are effective surgical procedures that could be performed when more conservative treatments fail. Laparoscopic cyst decortication has been well studied and results in relieving chronic renal pain in the majority of patients which will aid in segment’s growth during the forecast period. Furthermore, renal denervation has been used successfully and can be performed alongside with cyst decortication. Nephrectomy should be kept limited for patients with intractable pain and renal failure when other modalities have failed.

By End User, which segment is expected to dominate the market?

Hospitals driving growth with significant market share

Hospitals segment is anticipated to contribute to highest revenue share of around 54% by end of the forecast period. The growth is attributable to high patient pool, robust healthcare infrastructure, easy accessibility of advanced machinery for dialysis and kidney stones, high availability of skilled healthcare professionals.

Furthermore, the first line therapies that are suggested by urologists and other healthcare specialists are generally available in hospital environments. Thus, it is expected to drive the segment’s growth during the forecast period.

Start-ups in Autosomal dominant polycystic kidney disease treatment market

Start-ups help in determining the future growth opportunities in any market. These new entrants have the potential to generate high returns which directly benefits the expansion of any industry. These start-ups are typically more efficient at transforming inputs into outputs with more flexibility and adaptability in nature, able to shift quickly in response to sensitive market conditions. Some of the start-ups that will bolster the expansion of Autosomal dominant polycystic kidney disease treatment market are:

• Palladio Biosciences is a Newtown Square, United States-based start-up that was founded in 2016. This start-up is developing medicines for orphan diseases of kidney including Polycystic kidney disease. The company’s lead product is lixivaptan, a selective vasopressin V2 receptor antagonist currently in development for the treatment of polycystic kidney disease (Phase 2). It received funding of US$ 28 million from Samsara Bio Capital, Osage University Partners, and 2 others.
• Founded in 2007, Regulus Therapeutics is a San Diego, United States based company that is focused on the discovery and development of microRNA therapeutics. This company is developing RG-101, an anti-miR for the treating Hepatitis C and RG-012, an anti-miR for treating Alport syndrome, a life-threatening genetic kidney disease. It is also advancing in various programs toward clinical development in oncology, fibrosis and metabolic diseases, both independently and with alliance partners. Each anti-miR is designed to bind with and inhibit a specific microRNA target that is up-regulated in a cell and that is included in the disease state. This start-up was granted funding of USD 35 million from New Enterprise Associates and Federated Hermes.
• Founded in 2010, Primrose Therapeutics is a New York, United States-based biotechnology company focused on the development of treatments for Polycystic Kidney Disease (PKD). The average life expectancy of these patients is 64 years – at least a decade lesser than average. No Food and drug administration approved therapies presently exist for this devastating disease. This company was bought by stemline therapeutics in Sep 2011. It gathered total funding of USD 753 K.

Market Competition

The autosomal dominant polycystic kidney disease treatment market is intesely competitive and consists of several industry players. These players are developing novel delivery systems for treating Autosomal dominant polycystic kidney disease treatment. This is estimated to propel Autosomal dominant polycystic kidney disease treatment market. The key players in this industry are: Otsuka Pharmaceutical, Sanofi, Reata Pharmaceuticals, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, Xortx Therapeutics, AceLink Therapeutics, Inc, PanoTherapeutics, Inc, and Exelixis, Inc.

To stay in the forefront of highly competitive market, the key market players are focusing on expanding their geographical reach and investing in product development. The practice of adopting organic as well as inorganic strategies by the players help the polycystic kidney disease treatment market to grow at a significant growth rate. This is anticipated to fuel the global Autosomal dominant polycystic kidney disease treatment market.

• In July 2022, Grupo Olmos which is a provider of renal care solutions, declared that the company had acquired renal care business of Diaverum, a renal healthcare provider, that operates in Argentina. This acquisition will strengthen the renal product portfolio of the company.
• In 2020, Palladio Biosciences declared about the first patient of autosomal dominant polycystic kidney disease dosed with lixivaptan which is a novel vasopressin V2 antagonist. They assured the safety of lixivaptan in these patients who earlier discontinued therapy with tolvaptan due to liver toxicity.
• In March 2019, Aster Hospitals, the biggest private healthcare service providers operating in multiple GCC states, declared that it had launched an awareness and screening initiative to promote the prevention of chronic kidney disease through education, awareness, and early diagnosis.
• In August 2022, Bayer announced launch of finerenone drug to treat chronic kidney disease associated with type-2 diabetes in India.
• In July 2022, Health Canada accepted GlaxoSmithKline's new drug submission for daprodustat which is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with anemia of chronic kidney disease

Report Scope

Key Segments Profiled in the Autosomal Dominant Polycystic Kidney Disease Treatment Industry Survey

By Treatment Type:

• Pain & Inflammation Treatment
• Kidney Stone Treatment
• Urinary Tract Infection Treatment
• Kidney Failure Treatment

By End User:

• Hospitals
• Clinics
• Ambulatory Surgical Centers

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa